Dose-dependent augmentation effect of bromocriptine in a case with refractory depression.
1. A 52-year-old female with refractory depression had not responded to various treatments including electroconvulsive therapy and augmentation therapy with lithium or triiodothyronine. 2. Addition of bromocriptine 2.5-5 mg/day to imipramine improved her depressive symptoms. However, when the dose was increased to 15 mg/day to treat residual depressive symptoms, her clinical status deteriorated and returned to the original level. The dose reduction to 5mg/day again improved her depressive symptoms. 3. This report confirms the augmentation effect of bromocriptine for refractory depression. It also suggests that there is dose-dependency in this effect.
Wada
T
T
Department of Neuropsychiatry, Yamagata University School of Medicine, Japan.
Kanno
M
M
Aoshima
T
T
Otani
K
K
D001971:Bromocriptine / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004565:Electroconvulsive Therapy; D005260:Female; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D008875:Middle Aged; D014284:Triiodothyronine / Q000627:therapeutic use*
D018491:Dopamine Agonists; D014284:Triiodothyronine; D001971:Bromocriptine; D008094:Lithium